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Sperandio PA, Oliveira MF, Rodrigues MK, Berton DC, Trep-
tow E, Nery LE, Almeida DR, Neder JA. Sildenafil improves
microvascular O2 delivery-to-utilization matching and accelerates
exercise O2 uptake kinetics in chronic heart failure. Am J Physiol
Heart Circ Physiol 303: H1474–H1480, 2012. First published Sep-
tember 28, 2012; doi:10.1152/ajpheart.00435.2012.—Nitric oxide
(NO) can temporally and spatially match microvascular oxygen (O2)
delivery (Q˙ O2mv) to O2 uptake (V˙ O2) in the skeletal muscle, a crucial
adjustment-to-exercise tolerance that is impaired in chronic heart
failure (CHF). To investigate the effects of NO bioavailability induced
by sildenafil intake on muscle Q˙ O2mv-to-O2 utilization matching and
V˙ O2 kinetics, 10 males with CHF (ejection fraction  27  6%)
undertook constant work-rate exercise (70–80% peak). Breath-by-
breath V˙ O2, fractional O2 extraction in the vastus lateralis {deoxy-
genated hemoglobin  myoglobin ([deoxy-Hb  Mb]) by near-
infrared spectroscopy}, and cardiac output (CO) were evaluated after
sildenafil (50 mg) or placebo. Sildenafil increased exercise tolerance
compared with placebo by20%, an effect that was related to faster on-
and off-exercise V˙ O2 kinetics (P  0.05). Active treatment, however,
failed to accelerate CO dynamics (P  0.05). On-exercise [deoxy-Hb 
Mb] kinetics were slowed by sildenafil (25%), and a subsequent
response “overshoot” (n  8) was significantly lessened or even abol-
ished. In contrast, [deoxy-Hb  Mb] recovery was faster with sildenafil
(15%). Improvements in muscle oxygenation with sildenafil were
related to faster on-exercise V˙ O2 kinetics, blunted oscillations in ventila-
tion (n  9), and greater exercise capacity (P  0.05). Sildenafil intake
enhanced intramuscular Q˙ O2mv-to-V˙ O2 matching with beneficial effects
on V˙ O2 kinetics and exercise tolerance in CHF. The lack of effect on CO
suggests that improvement in blood flow to and within skeletal muscles
underlies these effects.
sildenafil; blood flow; heart failure; hemodynamics; near-infrared
spectroscopy; oxygen consumption; kinetics
THE INABILITY TO MAINTAIN an adequate driving pressure for
blood-myocite oxygen (O2) diffusion [i.e., microvascular par-
tial pressure of O2 (PO2mv)] is paramount to explain the
slowness of exercise O2 uptake (V˙ O2) kinetics in patients with
chronic heart failure [CHF; as recently reviewed by Poole and
colleagues (34)]. To keep a sufficiently high PO2mv, however,
O2 delivery should be spatially and temporally matched to V˙ O2
of individual fibers. In this context, seminal studies found that
intramuscular PO2mv in rodents with CHF was critically low
either at rest-to-contractions transition (7, 14) or during early
recovery (12), i.e., when V˙ O2 should be increasing or decreas-
ing most rapidly, respectively. Importantly, it was demon-
strated that reduced nitric oxide (NO) bioavailability exerted a
key mechanistic role on on- and off-exercise O2 delivery-to-
utilization uncoupling in these animal preparations (24, 25).
In intact humans with CHF, previous studies have concom-
itantly assessed the rate of change in phase II (“muscle”) V˙ O2
(39) and intramuscular fractional O2 extraction {deoxygen-
ated hemoglobin  myoglobin ([deoxy-Hb  Mb]) by near-
infrared spectroscopy (NIRS)} (18) to gain insight into the
dynamic matching of O2 delivery to utilization (9, 10, 37). This
analysis is based on the widely accepted concept that PO2mv
and changes thereof reflect the delivery/utilization ratio, i.e.,
V˙ O2/microvascular O2 delivery (Q˙ O2mv) as deoxygenation (18).
In fact, decreases in O2 delivery relative to O2 needs speeded
(and heightened) on-exercise [deoxy-Hb  Mb] kinetics but
slowed postexercise [deoxy-Hb  Mb] recovery in patients
with CHF (9, 10, 37). The therapeutic potential of increasing
NO bioavailability to improve the dynamic coupling of Q˙ O2mv
to V˙ O2, thereby accelerating V˙ O2 kinetics and enhancing exer-
cise tolerance, however, remains unexplored in these patients.
Moreover, considering that stimulation of muscle metabore-
ceptors by hypoxia-related by-products might further increase
the ventilatory drive, thereby predisposing to oscillatory
breathing, it could be hypothesized that better O2 delivery-to-
utilization matching induced by NO could contribute to breath-
ing stability in CHF (23).
In the present study, therefore, we aimed to investigate the
effects of increased NO bioavailability through acute pharma-
cological inhibition of muscle cGMP-specific phosphodiester-
ase-5 (PDE5) (32) by sildenafil intake (20) on peripheral
muscle Q˙ O2mv-to-V˙ O2 matching and V˙ O2 kinetics at the transi-
tion to and from constant work-rate exercise in patients with
stable CHF. We hypothesized that compared with placebo,
sildenafil would improve muscle oxygenation and accelerate
V˙ O2 kinetics with positive consequences on exercise tolerance
in these patients.
METHODS
Subjects. This was a prospective study involving 10 nonsmoking
men recruited from the CHF Outpatients Clinic of The São Paulo
Hospital, Federal University of São Paulo. Patients had an established
diagnosis of CHF (ischemic or idiopathic cardiomyopathy) for at least
4 yr, three-dimensional echodopplercardiography showing left-ventri-
cle ejection fraction 35%, and New York Heart Association func-
tional classes II–III (Table 1). No patient had cardiac resynchroniza-
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tion therapy or a left-ventricle assist device. Patients were excluded
from the study if they had clinical and/or functional evidences of
chronic expiratory flow limitation (forced expiratory volume in 1
s/forced vital capacity ratio 0.7), anemia (actual Hb values as 15.5
 1.4 g%), unstable angina or significant cardiac arrhythmias, and
myocardial infarction within the previous 12 mo. Renal function
parameters were: serum creatinine  1.2  0.2 g/dl, estimated
glomerular filtration rate (Cockroft-Gault)  67.1  8.7 ml·min1
·1.73 m2, and urea  48.4  17.2 mg/dl. Study participants gave a
written, informed consent, and the study protocol was approved by the
Institutional Medical Ethics Committee.
Study protocol. After familiarization, subjects performed an indi-
vidualized ramp-incremental exercise test (5–10 W/min) to determine
the difference between V˙ O2 at the gas exchange threshold (GET; by
the V-slope method) and V˙ O2 at peak exercise (V˙ O2peak-GET). On
different days, subjects underwent a constant work-rate exercise test
to the limit of tolerance (Tlim; s) at a V˙ O2 equivalent to 40–50% of
the V˙ O2peak-GET (70–80% peak work rate if the GET was not
identified) 1 h after sildenafil (50 mg) or placebo intake.
Cardiopulmonary exercise testing. The tests were performed on an
electronically braked cycle ergometer (Corival 400, Lode, The Neth-
erlands) at 50  5 rpm, and they were preceded and followed by
unloaded pedaling at 0 W for 3 min. V˙ O2 (ml/min), carbon dioxide
(CO2) output (V˙ CO2; ml/min), minute ventilation (V˙ E; l/min), and
end-tidal partial pressures for CO2 (mmHg) were measured breath by
breath (CardiO2 System, Medical Graphics, St. Paul, MN). During the
incremental test, values were averaged as arithmetic mean of 20 s, and
peak V˙ O2 was the highest mean value recorded. The relationship
between the rates of changes in V˙ E and V˙ CO2 (V˙ E/V˙ CO2) was
established from unloaded exercise to the respiratory compensation
point. Exercise oscillatory breathing, either during incremental or
constant work-rate tests, was assumed as present when oscillations
occurred 60% of exercise data at an amplitude 15% of resting
values with minimal average amplitude of 5 l/min, and there was a
regular oscillation (SD of three consecutive cycle lengths within 20%
of the average) (31).
Skeletal muscle oxygenation. Skeletal muscle oxygenation profiles
of the left vastus lateralis were evaluated with a commercially avail-
able NIRS system (Hamamatsu NIRO-200, Hamamatsu Photonics,
Japan). The methodology of continuous-wave NIRS has been de-
scribed elsewhere (16). Among the NIRS variables, [deoxy-Hb 
Mb] has been used as a proxy of fractional O2 extraction in the
microcirculation, reflecting the balance between O2 delivery and
utilization (18, 37). To improve intra- and intersubject comparability,
values (	M/cm) were recorded as a delta () and expressed relative
(%) to the amplitude of variation from baseline to the steady state
(within 2 SD of the local mean) with placebo.
Central hemodynamics. Cardiac output (CO) was measured through-
out the constant work-rate tests using a calibrated signal-morphology
impedance cardiography device (PhysioFlow PF-05, Manatec Biomedi-
cal, France). Values were recorded as mean of seven beats, as indicated
by the manufacturer. The PhysioFlow device and its methodology have
also been described in detail elsewhere (11). In preliminary experiments,
the coefficient of variation (CV) for changes in CO during exercise was
3.3%, and stepwise changes in CO were consistent with those predicted
from V˙ O2 values, as described previously in CHF patients (27). Values
(l/min) were recorded as a delta () from baseline and expressed relative
(%) (27) to amplitude of variation from baseline to the steady state
(within 2 SD of the local mean) after placebo.
Data analysis. The breath-by-breath V˙ O2, [deoxy-Hb  Mb], and
CO data were time aligned to the start of exercise to 180 s after
exercise cessation and interpolated second by second. Breaths outside
4 SD of the local V˙ E mean were deleted, and V˙ O2 was averaged into
5-s bins to further improve signal stability (26). The kinetics of these
responses were determined by nonlinear regression using a least-
square technique (Marquardt-Levenberg; SigmaPlot 10.0, Systat Soft-
ware, San Jose, CA).
Exercise onset. V˙ O2 was fitted from 30 s of baseline pedaling to 180
s after the onset of exercise. For [deoxy-HbMb] kinetics, the analyses
were conducted on data from 30-s baseline cycling to the steady-state
response. The model used for fitting the kinetic response of V˙ O2 and
[deoxy-Hb  Mb] without an “overshoot” (see below) was
Yt Yb A · 1 e
tTD⁄6 (1)
where b refers to baseline-unloaded cycling, and A, TD, and 
 are the
amplitude, time delay, and time constant of the exponential response
(i.e., time to reach 63% of the final value), respectively. For V˙ O2
analysis, we deleted the data relative to the cardiodynamic phase (9).
The overall kinetics of V˙ O2 and [deoxy-Hb  Mb] were determined
by the mean response time (MRT)  
  TD. For CO, we calculated
the one-half time (t1/2; s), and an estimate of MRT was obtained as
t1/2  1.44. A two-component, monoexponential model was applied
to [deoxy-Hb  Mb] data with an overshoot (4, 10, 18)
Yt YbA1 · 1 e
tTD1⁄1 A2 · 1 etTD2⁄2
(2)
where the subscripts 1 and 2 correspond to the two sequential com-
ponents (upward and downward, respectively). The area under the
[deoxy-HbMb] overshoot (AUC; a.u.) and a longer 
2 (Eq. 2) were
used as additional indicators of impaired Q˙ O2mv-to-V˙ O2 matching (4)
(Fig. 1). On preliminary trials, the CV for the kinetic parameters of the
[deoxy-Hb  Mb] response ranged between 5% and 11% [first test 
second test mean bias and range: 
  0.3 s (0.3 s to 0.8 s), and
TD  0.1 s (0.4 s to 0.5 s)].
Exercise recovery. We used data from the last 30 s of exercise to
180 s of recovery to calculate the kinetics of the primary component
Table 1. Resting and peak exercise data (n  10)
Variables Values
Anthropometrics/Demographics
Age, yr 57.2 12.3
Body mass, kg 72.5 11.0
Body mass index, kg/m2 25.2  4.3
Etiology
Ischemic 4
Idiopathic dilated cardiomyopathy 6
Echocardiography
Left-ventricle ejection fraction, % 27.4 6.6
Drugs
Diuretics 9
Spironolactone 9
Digitalis 2
Carvedilol 10
ACE inhibitors/AR blockers 10
Incremental exercise
At peak
Work rate, W 82  12
V˙ O2, ml/min 1,069  261
V˙ O2, ml · min1 · kg1 14.7  2.7
V˙ O2, % pred 56.3  12.6
HR, beats/min 116 28
HR, % pred 75.2  12.8
O2 pulse (ml · min1 · beat1) 9.6  3.0
Mean arterial pressure, mmHg 102 19
Submaximal variables
V˙ E/V˙ CO2 slope 46.3  7.4
V˙ O2/work rate (ml · min1 · W1) 8.2  1.9
V˙ O2GET, ml/min 653  131
ACE, angiotensin-converting enzyme; AR, angiotensin receptor; V˙ O2, oxy-
gen (O2) uptake; pred, predicted; HR, heart rate; , variation; V˙ E, minute
ventilation; V˙ CO2, carbon dioxide (CO2) output; GET, gas exchange threshold.
Values are means  SD.
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of response. The model used for fitting the kinetic response of V˙ O2
and [deoxy-Hb  Mb] was [Y](t)  [Y](ss)  A·[1  e(t  TD)/
].
MRT of [deoxy-Hb  Mb] and CO was determined as described
above. On preliminary trials, the CV for the kinetic parameters of the
[deoxy-Hb  Mb] response ranged between 3% and 6% [first test 
second test mean bias and range: 
  3.4 s (1.9 s to 7.9 s), and
TD  1.2 s (1.4 s to 2.7 s)].
Statistical analysis. Results were summarized as mean  SD. The
primary end point of the study was changes in on-exercise MRT-
[deoxy-Hb  Mb] after sildenafil when compared with placebo.
Secondary end points included Tlim, AUC (Eq. 2), 
-V˙ O2/MRT-
[deoxy-Hb  Mb], V˙ O2 kinetics, and amplitude of oscillatory
breathing. To contrast within-subject resting and exercise responses,
paired t- or Wlicoxon tests were used as appropriate. Pearson’s
product moment correlation was used to assess the level of association
between continuous variables. The level of statistical significance was
set at P  0.05 for all tests.
RESULTS
Peak exercise capacity. Peak work rate and V˙ O2 of all
patients were below the age- and gender-corrected lower limits
of normality. Eight patients were on Weber’s class C and two
on class B. The GET was identified in all but two subjects. As
anticipated by the long-term -blocker therapy, patients
showed impaired peak heart rate (Table 1). Exercise oscillatory
breathing (31) was present in all but one patient during the
incremental and constant work-rate exercise tests.
On- and off-exercise response dynamics after placebo. All
fitted data were included in the kinetics analysis, as coefficient
of determination values ranged from 0.90 to 0.99. On- and
off-exercise V˙ O2 and CO kinetics with placebo were slower
than reported previously in healthy males of similar age (10)
(Table 2). On-exercise CO kinetics were consistently slower
than V˙ O2 dynamics, whereas off-exercise rates of change were
remarkably similar (Fig. 2). There were significant relation-
ships between these variables both at the onset of and during
recovery from exercise (R  0.69, and R  0.81, respectively;
P  0.05).
At the onset of exercise, [deoxy-HbMb] increased rapidly
with a rate of change that was faster than the V˙ O2 and CO
responses. In contrast, MRT-[deoxy-Hb  Mb] during recov-
ery did not differ from MRT-V˙ O2 and MRT-CO (Fig. 2). An
overshoot in [deoxy-Hb  Mb] was identified in eight of 10
patients (see Fig. 1 for a representative patient). AUC and the
kinetics of its downward component were inversely related to
on-exercise 
-V˙ O2 (R  0.80, and R  0.73, respectively; P 
0.05).
Effects of sildenafil on exercise tolerance and physiological
responses. Sildenafil increased Tlim compared with placebo by
20% (P  0.05; Table 3). Despite a lack of effect on the
cardiopulmonary responses at exercise cessation (Table 3),
sildenafil significantly decreased the amplitude of V˙ E oscilla-
tions (% of mean) and their cycle length (21.4  15.2% vs.
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Fig. 1. Skeletal muscle deoxygenated hemoglobin myoglobin ([deoxy-Hb
Mb]) profiles at the onset of constant work-rate exercise after placebo (Œ) and
sildenafil () intake in a representative patient with chronic heart failure
(CHF). Values are expressed relative to the amplitude of the coefficient of
variation from baseline to the steady state with placebo. TD, time delay; 
1,
time constant of the upward component; 
2, time constant of the downward
component; OS, overshoot.
Table 2. On- and off-exercise kinetic parameters for V˙ O2, [deoxy-Hb/Mb], and cardiac output after placebo or sildenafil
intake (n  10)
Placebo Sildenafil
On-Exercise Off-Exercise On-Exercise Off-Exercise
V˙ O2
Baseline, ml/min 512  149 985 204* 544  174 1,015  201*
Amplitude, ml/min 459 187 361 168 427  103 432  119

, s 54.3  10.4 62.9 19.4* 41.3  12.1† 52.1  15.7*,†
TD, s 14.1  8.7 16.4 12.2 15.7  9.9 13.7  10.1
[deoxy-Hb/Mb]
Baseline, % 1.8  3.3 101.1  14.4* 1.2  2.9 90.4  10.9*,†
Amplitude, % 118.8  10.7 60.6 18.3* 89.1  11.3† 40.7  15.1*,†

, s 5.7  2.1 58.9 20.3* 10.2  2.8† 50.1  17.0*,†
TD, s 10.9  4.7 13.8 9.7 12.4  5.1 12.7  8.9
Cardiac output
Baseline, % 0.9  5.4 103.4 11.9* 1.3  6.1 103.4  11.9*
Amplitude, % 103.4  11.9 69.5 15.7* 101.1  14.3 70.9  12.1*
t1/2, s 53.6  9.4 58.3 12.2 55.9  10.7 53.1  11.9
[deoxy-Hb/Mb], deoxygenated hemoglobin/myoglobin; 
, time constant; TD, time delay; t1/2, 1/2-time. Values are means  SD. [deoxy-Hb/Mb] and cardiac
output values are expressed relative to steady state  baseline variation on placebo. *P  0.05 for on- vs. off-exercise within a given treatment; †P  0.05 for
between-treatment differences within a given time point.
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50.8  10.4% and 19.9  10.7% vs. 48.3  12.1% for
sildenafil and placebo, respectively). In addition, the number of
cycles was reduced in two patients, and oscillatory breathing
disappeared in other two patients.
On- and off-exercise V˙ O2 kinetics were accelerated by silde-
nafil intake (Table 2 and Figs. 2–4). There was a significant
relationship between  (sildenafil-placebo) Tlim with treat-
ment-induced decrements in 
-V˙ O2 (R  0.68; P  0.05). In
contrast, sildenafil failed to accelerate CO dynamics either at
the onset of or recovery from exercise (Table 2 and Fig. 2).
Consequently, V˙ O2 and CO kinetics were no longer correlated
after sildenafil treatment (P  0.05).
On-exercise [deoxy-Hb  Mb] kinetics were slowed by
sildenafil (25%; Table 2 and Fig. 2), and the AUC was lessened
[median (range) 2,085 (857–3,115) a.u. vs. 428 (125–628) a.u.;
P  0.05] or even abolished (n  2; Fig. 1). Consequently,

-V˙ O2/MRT-[deoxy-Hb  Mb] after sildenafil was lower at
the onset of exercise compared with placebo (1.77  0.89 s vs.
3.31  1.0 s, respectively; P  0.05). In addition, [deoxy-Hb 
Mb] recovery was faster with sildenafil (15%; Table 2 and Fig.
2). Interestingly, improvement in on-exercise muscle oxygenation
VO2 CO [deoxy-Hb+Mb]
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Fig. 2. Mean response time (MRT) of oxygen (O2) uptake (V˙ O2), cardiac
output (CO), and [deoxy-Hb Mb] at the onset of and recovery from exercise
after placebo (open bars) and sildenafil (solid bars) intake in patients with
CHF. Data are mean (SD). *P  0.05 for between-treatment comparisons on
a given time point; †P  0.05 for onset vs. recovery on a given treatment;
‡P  0.05 for CO vs. V˙ O2 and [deoxy-Hb  Mb] at a given time point; §P 
0.05 for V˙ O2 vs. [deoxy-Hb  Mb] at a given time point.
Table 3. Main physiological responses just prior to exercise
cessation after placebo or sildenafil intake (n  10)
Placebo Sildenafil
Tlim, s 435  267 529 405*
V˙ O2, ml/min 972  212 1,008 208
V˙ CO2, ml/min 1,113  260 1,112 262
RER 1.15  0.15 1.10 0.14
V˙ E, l/min 49.4  14.5 46.8 12.1
V˙ E/V˙ O2 51.0  11.6 46.8 8.2
V˙ E/V˙ CO2 44.5  8.3 42.6 7.1
PETCO2, mmHg 27.4  5.7 28.0 4.6
HR, beats/min 117 25 114 18
HR, % pred 74.4  11.8 73.7 14.1
Systolic blood pressure, mmHg 128 22 124 18
Diastolic blood pressure, mmHg 75 11 79 11
Mean arterial pressure, mmHg 103 20 97  15
Tlim, time-to-exercise intolerance; RER, respiratory exchange ratio; PETCO2,
end-tidal partial pressure for CO2. Values are means  SD. *P  0.05.
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Fig. 3. Time course of V˙ O2 at the onset of exercise after placebo (Œ) and
sildenafil intake () in patients with CHF. Values were averaged in 10-s bins
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with active treatment {i.e., higher  (sildenafil-placebo) MRT-
[deoxy-Hb  Mb]} was related to larger decrements in the
amplitude of V˙ E oscillations (R0.66; P 0.045), faster V˙ O2
kinetics (Fig. 5, top), and greater increases in exercise tolerance
(Fig. 5, bottom).
DISCUSSION
This study is the first to demonstrate that compared with
placebo, acute PDE5 inhibition with sildenafil led to a closer
matching between intramuscular O2 delivery and utilization
during the transition to and from constant work-rate exercise in
patients with CHF. These beneficial consequences of active
treatment speeded pulmonary V˙ O2 kinetics, which suggests that
peripheral muscle V˙ O2 kinetics were faster, reduced the ampli-
tude of oscillatory breathing, and increased exercise capacity.
Improvements in muscle oxygenation and aerobic metabolism
were not related to changes in CO dynamics, thereby suggest-
ing that blood flow redistribution to and within the working
muscles underlies these effects.
CHF-related O2 delivery-to-utilization mismatching. Dis-
ease-induced decreases in O2 delivery relative to muscle O2
demands have been found to accelerate and amplify rest-to-
exercise decrements in PO2mv and to slow its recovery after
exercise (8, 12, 24, 25). This is physiologically equivalent to
faster and heightened on-exercise increases in microvascular
fractional O2 extraction ([deoxy-Hb  Mb], the mirror im-
age of PO2mv) and slower postexercise [deoxy-Hb  Mb]
recovery (9, 10, 18, 37). Moreover, fractional O2 extraction
transiently overshoots the subsequent steady-state value (Fig.
1) when O2 delivery is markedly delayed relative to O2 needs
(4, 9, 10, 18). All of these derangements are expected to
increase O2 deficit and promote metabolic abnormalities asso-
ciated with muscle fatigability and poor exercise tolerance
(34). The effects of sildenafil on these abnormal patterns of
intramuscular (de)oxygenation have not yet been determined in
patients with CHF.
Sildenafil on muscle Q˙ O2mv-to-V˙ O2 matching. The present
study describes a novel mechanism (improved Q˙ O2mv-to-V˙ O2
matching) to explain the ergogenic properties of sildenafil (5,
9a, 22) in patients with CHF. The first hypothetical explanation
for this finding is an increase in bulk muscle blood flow due to
faster CO dynamics. However, our data indicate that this was
not the case (Tables 2 and 3 and Fig. 2). In fact, Guazzi et al.
(22) were the first to show that increased V˙ O2/work-rate slope
and faster postexercise V˙ O2 kinetics with sildenafil were
loosely related to improvements in central hemodynamics.
These findings led the authors to hypothesize that CO had been
redistributed to skeletal muscles after sildenafil administration,
probably due to enhanced shear stress vasodilation in local
conduit vessels. This hypothesis makes sense under the view
that CHF is associated with impaired endothelial function and
reduced NO bioavailability (15, 28), and sildenafil can improve
flow-mediated vasodilation and local NO levels (21). Although
we did not measure blood flow through these vessels, this
might help to explain our findings of improved on- and off-
exercise muscle oxygenation despite unaltered CO dynamics.
However, vasodilation of feeding arteries is not an obligatory
requisite for a better dynamic coupling between Q˙ O2 and V˙ O2
at the capillary level; in fact, the time course of skeletal muscle
capillary hyperemia at the onset of exercise might differ
markedly from the increased blood flow through larger conduit
arteries (18, 35). Moreover, based on the stability of mean
arterial pressure (Table 3) and CO, it is unlikely that there was
a substantial decline in total peripheral vascular resistance after
sildenafil. It is conceivable, therefore, that even if bulk blood
flow increased with sildenafil (5, 21), it had the additional
effect of more precisely matching intramuscular Q˙ O2mv to V˙ O2;
i.e., active treatment might have redistributed blood flow
within the working muscles (34).
Role of NO on Q˙ O2mv-to-V˙ O2 matching. Diffusion of NO to
surrounding vascular smooth muscle cells activates local
cGMP, which induces vasodilation by inhibition of calcium
influx into the cell, activation of calcium-ATPase pumps, and
opening of potassium channels, thereby leading to hyperpolar-
ization and relaxation (15, 38). Interestingly, however, NO can
modulate not only Q˙ O2mv but also, through inhibition of cel-
lular respiration, muscle V˙ O2 (36). Therefore, by acting on both
determinants of tissue oxygenation (delivery and utilization),
NO is the “ideal” candidate to exert a commanding role in
muscle Q˙ O2mv-to-V˙ O2 matching (34). In line with the extensive
evidence derived from animal studies (17, 24, 25), increased
muscle NO bioavailability might have not only increased
Q˙ O2mv but also concomitantly decreased local O2 needs,
thereby allowing better temporal and spatial Q˙ O2mv-to-V˙ O2
matching and a faster rate of transcapillary O2 flux.
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(Tlim; bottom) in patients with CHF.
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Study implications and directions for future research. The
novel mechanistic explanation for the effects of sildenafil on
exercise tolerance in CHF provided in the present study
(Q˙ O2mv-to-V˙ O2 matching) may also help explain why measure-
ments of central hemodynamics are poorly predictive of the
ergogenic effects of sildenafil in these patients (21, 22). More-
over, our results open the perspective to combine sildenafil
with other strategies known to increase muscle NO bioavail-
ability [e.g., exercise training (2, 13) and L-arginine (30) or
dietary nitrate supplementation (3)] in future trials in CHF.
Considering that the speeding effect of sildenafil on postexer-
cise muscle deoxygenation might have accelerated the rate of
oxidative rephosphorylation (39), it seems interesting to inves-
tigate its value in improving patients’ ability to perform repet-
itive activities, which are probably relevant to patients’ daily
functioning. Our sample comprised middle age subjects not
older than 65 yr, and senescence is associated with further
reductions in muscle NO bioavailability in CHF (7, 34). There-
fore, we may have underestimated the beneficial effects of
sildenafil on Q˙ O2mv-to-V˙ O2 matching, an issue to be investi-
gated in older patients.
Confirming the reports of Guazzi and coworkers (22), we
found a marked decrease in exercise-related oscillatory breath-
ing with sildenafil, which was largely independent of changes
in CO. Although we are uncertain whether changes in pulmo-
nary vascular resistance and/or facilitation of intrapulmonary
gas diffusion after sildenafil played a mechanistic role in this
regard, improvements in oscillatory breathing and intramuscu-
lar oxygenation were significantly correlated. It is possible,
therefore, that less accumulation of metabolic by-products due
to better muscular O2 delivery-to-utilization matching reduced
activation of groups III and IV afferents and the ventilatory
drive, thereby contributing to breathing stability (9a, 19, 23,
33). Larger trials specifically powered to this issue are needed
to further investigate the potential relationships among im-
proved intramuscular O2 delivery-to-utilization coupling, en-
hanced muscle bioenergetics, decreased ergoreflex activation,
and lower exercise ventilatory stimuli in CHF.
Study limitations. We recognize that the small sample size
and the acute nature of the present study indicate that it remains
to be experimentally demonstrated whether the observed ben-
eficial effects of sildenafil could be extrapolated to less-severe
patients and whether they would be long lasting. These positive
results, albeit obtained in a selected group of stable patients,
now justify larger longitudinal investigations with a sizeable
number of patients with different degrees of disease severity to
look specifically at these physiological outcomes. It also re-
mains to be tested whether these effects of sildenafil intake can
also be reproduced in normal subjects.
As a noninvasive method, NIRS has a number of limitations
(as discussed extensively elsewhere) (16); however, it remains
the only available approach to interrogate the microcirculation
(small arterioles, capillary, and venules) during whole-body
exercise in intact humans. We restrained our analysis to [de-
oxy-Hb  Mb], as this variable is insensitive to blood volume
changes, and its time course has been found to be remarkably
equivalent to fractional O2 extraction when muscle venous
outflow is carefully isolated in animal preparations [as dis-
cussed at length in Barbosa et al. (4) and Ferreira et al. (17)].
A caveat particularly pertinent to the present study, however, is
its inability to differentiate Hb from Mb with regard to light
absorption. However, by comparing muscle deoxygenation
with PO2mv, determined by phosphorescence quenching within
the same muscle region in rat preparations, Koga et al. (29)
confirmed that the deoxygenation signal did provide a valid
index of local fractional O2 extraction kinetics during exercise
transients.
In the present study, we relied on a single exercise transition to
extract the parameters of V˙ O2 kinetics to avoid repetitive tests (and
drug intake) in a very disabled population. Although we recognize
that the signal-to-noise ratio would have been improved by aver-
aging multiple transitions (1, 26, 39), the supra-GET bout pro-
vided a response amplitude from baseline (0.5 l/min of V˙ O2 and
30 l/min of V˙ E), which was large enough for fidelity of param-
eters estimation while avoiding the confounding effects of the
ventilatory oscillations. Also, importantly, the effects of sildenafil
on on-exercise 
-V˙ O2 were commensurate with those found in
response to interventions in CHF (1) and above the test-to-test
variation in our laboratory during supra-anaerobic threshold ex-
ercise (10.2%).
Conclusions. Oversignaling of the NO pathway by PDE5
inhibition through a single dose of sildenafil enhanced on- and
off-exercise O2 delivery-to-utilization matching at the micro-
circulatory level, reduced the amplitude of oscillatory breath-
ing, and accelerated V˙ O2 kinetics with positive effects on
tolerance to endurance exercise in CHF. The lack of effect of
sildenafil on CO suggests that improvement in blood flow to
and within skeletal muscles is mechanistically linked to these
actions. Our data indicate that sildenafil is a drug particularly
suited to pathophysiology of CHF, as it enhances muscle
oxygenation and pulmonary V˙ O2 kinetics during exercise with-
out the need of major functional improvements in the failing
heart. Results of this cross-sectional investigation, however,
should be confirmed in larger longitudinal studies to assess the
long-term effects of sildenafil intake on these outcomes in
patients with different degrees of disease severity.
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